All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The MM Hub were delighted to attend the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation held in Lisbon, Portugal, from 18–21 March 2018. On Monday 19 March 2018 the oral abstract session 4 was held. The session was moderated by Catarina Geraldes, from the University of Coimbra, Portugal and Tamás Masszi, from Semmelweis University, Budapest, Hungary.
The third talk of this session was given by Stefan Schönland, from the University of Heidelberg, Heidelberg, Germany, who presented an abstract entitled: Improved survival after allogeneic stem cell transplantation for light chain amyloidosis: a retrospective analysis in 55 patients of the chronic malignancy working party (EBMT). This was a non-interventional clinical study (NIS) within ProMISe.
This study presents findings from the largest cohort of AL patients treated with allo-SCT. Allo-SCT showed feasibility and efficacy in selected AL patients, with a decrease in early mortality and long term survival. These findings confirm the beneficial use of allo-SCT with an HLA-identical donor in heavily pretreated young and fit MM patients with AL.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox